GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Is a Cell Batch Release Report?

A cell batch release report is a batch-specific quality document that records test results, acceptance criteria, and the decision on whether cells can be released for use. It connects a particular batch number to its testing and release approval. It is not proof that the treatment will work.

Before treatment, check that the report matches the cells intended for you, identifies the results used to authorize release, and names the person who approved that decision.

What Is a Cell Batch Release Report?

Which cells does the report cover?

A batch is a defined group of cells produced under controlled conditions. For cultured cell products, it may involve cells expanded from a particular donor sample during a production run. Whether the starting material comes from your own cells or another donor’s cells, the report must be traceable to the material intended for your treatment.

Compare the batch or lot number on the report with the treatment documentation and, through the clinical team, the product label. Also check the cell type, production date, expiry date, and any stated storage conditions. A report for another batch is not a substitute.

What should it contain?

Formats and test panels vary by product and jurisdiction. Use the following as a reading guide, not a universal legal checklist.

Report item What to look for What it helps you check
Batch identification Lot number, cell type, source reference, production and expiry dates Whether the document covers the cells intended for you
Cell count Total or viable cell count, units, and measurement method What the quoted cell number actually counts
Viability Percentage classified as alive, method, and testing time For illustration, 100 million total cells at 90% viability means about 90 million living cells by that test; this is not a release standard
Identity Tests for the expected cell characteristics Whether the tested cells match the stated identity; no single identity test rules out every possible problem
Purity Checks for unwanted cell populations or residual processing materials Which impurities were assessed and against what limits
Sterility Bacterial and fungal testing, sample date, result status, and completion date Which results were available at release and whether any final cultures were pending
Mycoplasma A specific test where applicable to the product and culture process Whether mycoplasma testing was addressed separately; FDA’s somatic-cell therapy guidance discusses this testing alongside sterility testing. Download
Endotoxin Measured result, units, and applicable limit Whether bacterial toxin levels met the product’s specification
Potency or functional testing Relevant biological activity, assay method, and criteria where established What activity was measured, without treating that laboratory result as proof of clinical benefit
Appearance and container Visual inspection and container integrity Whether abnormalities or damage were recorded
Release decision Approval status, date, authorized reviewer, and references to deviations or investigations Who authorized release and what records supported it

The report may summarize results held in separate laboratory records. Ask where you can find the methods, acceptance criteria, and explanations for any missing or pending result.

How do you interpret the numbers?

Read each result beside its acceptance criterion, units, method, and testing time. A number without those details is hard to interpret. Some criteria are qualitative, such as a specified negative result, rather than a numerical cutoff.

For mesenchymal stromal cells, the ISCT’s research characterization criteria include surface markers such as CD105, CD73, and CD90. These criteria are not a complete release specification for every cell product, and marker expression alone does not establish clinical effectiveness. 16923606 Ask which product-specific specification the report actually uses.

Endotoxin limits illustrate why units and dose matter. FDA’s technical guide describes the K/M calculation, with K of 5 EU/kg for non-intrathecal products and 0.2 EU/kg for intrathecal products; M incorporates the maximum dose per kilogram administered within a single hour. The applicable product standard must also be checked. Bacterial endotoxinspyrogens Do not compare two EU/mL limits without knowing the dose and route used in each calculation.

What does the release decision mean?

Release is a documented decision against established criteria, not simply a list of favorable numbers. If a result is outside specification, ask for the investigation and final disposition rather than accepting an unexplained replacement result.

FDA’s guidance for chemistry-based testing of CDER-regulated drugs distinguishes an initial out-of-specification result from a confirmed batch failure. It calls for investigation and rejects repeating tests until a passing result appears while ignoring the original failure. An initial abnormal result does not automatically establish that the batch must be rejected. Download This guidance is not a universal cell-therapy release rule; the relevant product requirements govern the decision.

For US human cells, tissues, and cellular and tissue-based products (HCT/Ps) subject to the relevant current good tissue practice requirements, 21 CFR 1271.265(c) requires a review of manufacturing and tracking records before distribution. The records must be reviewed for compliance with established release criteria, with the determination documented and dated by an authorized person. Section 1271.265

Can results still be pending?

For some short-shelf-life investigational cell products, final sterility culture results may not be available before administration. FDA’s somatic-cell therapy IND guidance describes an alternative approach using in-process testing and rapid microbial assessment, with continued final-product testing and a plan for a later positive result. This is a US investigational context, not permission for any clinic to omit testing. Download

Compare sampling, release, administration, and final-result dates. If something was pending at release, ask which criteria permitted release, who authorized it, how the final result was tracked, and what action would follow a positive result. A pending result is not a negative result.

What does it not prove?

A batch release report documents a quality decision. It does not establish that a treatment is effective or risk-free.

Evidence of benefit must relate to the condition being treated, the cell preparation, the route of administration, and the patient population. A release report cannot replace that clinical evidence.

Nor is it interchangeable with facility registration or a regenerative-medicine provision plan. Japan’s Act on the Safety of Regenerative Medicine distinguishes Class I, II, and III regenerative medicine and sets requirements for provision and manufacturing. Those administrative processes are different from a batch-specific release decision or proof of efficacy. En An approved product, an experimental intervention, and a privately offered clinic service must not be assumed to have the same evidence or regulatory status.

How can you use it before treatment?

Request the report or an understandable batch-specific summary before your appointment. If necessary, ask for a translation and an explanation from the clinical team. These questions keep the discussion tied to your cells:

  • Does the lot number match the treatment record and product label?
  • Which test methods, units, and acceptance criteria apply?
  • Which results supported release, and which were still pending?
  • Were any results out of specification, repeated, or invalidated, and where is the documented explanation?
  • Who authorized release, on what date, and which cell processing center issued the records?
  • Who will review the remaining results and contact you if a problem is found?

For example, if the clinic shows you a report with a different lot number, ask for the matching record. If a sterility row says “pending,” do not read it as “passed”: ask for the release rationale and follow-up plan. These are document-reading scenarios, not evidence that any particular clinic has made an error.

During the pre-treatment discussion, keep batch quality and treatment benefit as separate questions. A matching, understandable release record helps explain the quality decision; it cannot decide whether that treatment is appropriate for you.